arixtra study in new england journal Overnight gsk announced...

arixtra study in new england journal Overnight gsk announced that the Arixtra ACS study was reported in the New England Journal of Medicine. The more Arixtra gets known about, the better.
Here's a snippet of their ann, for those interested:

...............
Arixtra® significantly reduced major bleeding compared to Lovenox® in a study of patients with acute coronary syndromes

Head-to-Head Data Published in New England Journal of Medicine Report:


PHILADELPHIA, PA, April 6, 2006 — Data published today in the New England Journal of Medicine from OASIS 5, one of the largest clinical trials ever conducted in patients with acute coronary syndromes (ACS),demonstrated that treatment with the antithrombotic medicine, ARIXTRA® (fondaparinux sodium) significantly reduced major bleeding by nearly half (48 percent) as compared to Lovenox® at day 9. The resultsshowed ARIXTRA, manufactured by GlaxoSmithKline, demonstrated comparable efficacy to Lovenox® at day 9.